Adverum Biotechnologies

Adverum Biotechnologies is a clinical-stage biotech focused on establishing gene therapy as a transformative treatment for prevalent ocular diseases, starting with wet age-related macular degeneration (wet AMD). The company's strategy leverages a proprietary intravitreal AAV vector platform to create 'biofactories' within the eye, aiming to replace the current burdensome regimen of frequent anti-VEGF injections with a one-time, in-office therapy. Its lead candidate, Ixo-vec, is in late-stage development with the goal of providing sustained therapeutic benefit for years, potentially restoring vision and preventing blindness for millions of patients.

A proprietary intravitreal (IVT) adeno-associated virus (AAV) vector platform engineered for efficient transduction of retinal cells to create sustained, in vivo production of therapeutic proteins from a single administration.

Adverum faces direct competition from Regenxbio/AbbVie's RGX-314 (intravitreal AAV) and 4DMT's 4D-150, as well as evolving standards of care like Roche's Vabysmo and Susvimo. Its differentiation rests on its proprietary vector, aflibercept transgene, and goal of multi-year durability from a single office-based procedure.